November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Weekly CagriSema Injection Combination Yields Significant Weight Loss in Phase IIIb Trial

🥗 Nutrition 2 min read 👁 4

A clinical trial published in The Lancet Diabetes & Endocrinology reports that two lower doses of the investigational injection CagriSema led to substantial weight reduction in adults with obesity or overweight.

Weekly CagriSema Injection Combination Yields Significant Weight Loss in Phase IIIb Trial🥗Nutrition

Photo: Medical Xpress

Key points

  • REDEFINE 9 trial evaluated CagriSema in 309 adults over 68 weeks.
  • Average weight loss reached over 20% for active treatment groups.
  • CagriSema remains an investigational treatment requiring further trials.

A recent Phase IIIb clinical trial published in The Lancet Diabetes & Endocrinology has demonstrated that weekly injections of CagriSema—a combination of two appetite-suppressing agents, cagrilintide and semaglutide—may significantly reduce body weight in adults living with obesity or overweight who also have a weight-related medical condition such as high blood pressure or sleep apnea. The 68-week study, known as REDEFINE 9, examined 309 participants across international sites in the U.S., U.K., Canada, France, and Germany, combining the medication regimen with lifestyle counseling on diet and physical exercise.

According to the findings, participants who maintained treatment achieved an average weight loss of 20.7% at a 1.7 mg dosage and 21.0% at a 1.0 mg dosage, contrasted with a 2.0% reduction seen in the placebo group. Furthermore, roughly half of those receiving the active treatment lost at least 20% of their baseline body weight, alongside notable decreases in waist circumference. The study authors indicate that these results point toward potential dosing flexibility for personalized care strategies, though they note that CagriSema remains investigational and requires additional study in larger and more diverse populations.

What to know: While these findings highlight potential advancements in weight management pharmacotherapy, the research represents an early-stage exploration involving a specific demographic. Readers are advised to consult a qualified healthcare professional before making any personal medical or lifestyle decisions.

Source Medical Xpress — medicalxpress.com/news/2026-11-weekly-weight-loss-combo.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.